SW
LEGN icon

SVB Wealth’s Legend Biotech LEGN Stock Holding History

SVB Wealth’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-154
Closed -$5.22K – 1119
2025
Q1 		$5.22K Buy
+154
New +$5.52K ﹤0.01% 1018

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

SVB Wealth's LEGN Position: Q2 2025 in Review

SVB Wealth sold out of Legend Biotech (LEGN) in Q2 2025, closing a stake of 154 shares — an estimated $5.22K sold.

SVB Wealth first reported a position in LEGN in Q1 2025 and held it in 1 quarter. The position peaked at $5.22K in Q1 2025. 210 funds tracked by Wall St. Rank hold LEGN as of Q2 2025.

  • SVB Wealth reported no remaining Legend Biotech position as of Q2 2025 after selling out during the quarter.
  • SVB Wealth sold 154 Legend Biotech shares in Q2 2025, an estimated $5.22K.
  • SVB Wealth first reported a position in Legend Biotech in Q1 2025 and held it in 1 quarter.
  • SVB Wealth's Legend Biotech position peaked at $5.22K in Q1 2025.
  • 210 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2025.

Based on SVB Wealth's 13F filing for Q2 2025, filed 14 Aug 2025.